Jihane Basbous

Dr. Jihane Basbous

Institute of Human Genetics (IGH), Univ Montpellier, CNRS UMR 9002 Montpellier, France
orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 December 2002 in Journal of Virology
Verified
Journal Article
Closed access
PDF file
GGGilles Gaudray
Gilles Gaudray
FGFrederic Gachon
Frederic Gachon
JBJihane Basbous
Jihane Basbous
MBMartine Biard-Piechaczyk
Martine Biard-Piechaczyk
CDChristian Devaux
Christian Devaux
JMJean-Michel Mesnard
Jean-Michel Mesnard
The RNA genome of the human T-cell leukemia virus type 1 (HTLV-1) codes for proteins involved in infectivity, replication, and transformation. We report in this study the characterization of a novel viral protein encoded by the complementary strand of the HTLV-1 RNA genome. This protein, designated HBZ (for HTLV-1 bZIP factor), contains a N-terminal transcriptional activation domain and a leucine zipper motif in its C terminus. We show here that HBZ is able to interact with the bZIP transcription factor CREB-2 (also called ATF-4), known to activate the HTLV-1 transcription by recruiting the viral trans -activator Tax on the Tax-responsive elements (TxREs). However, we demonstrate that the HBZ/CREB-2 heterodimers are no more able to bind to the TxRE and cyclic AMP response element sites. Taking these findings together, the functional inactivation of CREB-2 by HBZ is suggested to contribute to regulation of the HTLV-1 transcription. Moreover, the characterization of a minus-strand gene protein encoded by HTLV-1 has never been reported until now.

1 January 2014 in Cell
Verified
Journal Article
Closed access
NLNadine Laguette
Nadine Laguette
CBChristelle Brégnard
Christelle Brégnard
PHPauline Hue
Pauline Hue
JBJihane Basbous
Jihane Basbous
AYAhmad Yatim
Ahmad Yatim
MBMonsef Benkirane
Monsef Benkirane

1 October 2003 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
JBJihane Basbous
Jihane Basbous
CACharlotte Arpin
Charlotte Arpin
GGGilles Gaudray
Gilles Gaudray
MPMarc Piechaczyk
Marc Piechaczyk
CDChristian Devaux
Christian Devaux
JMJean-Michel Mesnard
Jean-Michel Mesnard
The human T-cell leukemia virus type I (HTLV-I)-encoded Tax protein activates transcription from the viral promoter via association with the cellular basic leucine zipper factor cAMP-response element-binding protein-2. Tax is also able to induce cellular transformation of T lymphocytes probably by modulating transcriptional activity of cellular factors, including nuclear factor-κB, E2F, activator protein-1 (AP-1), and p53. Recently, we characterized in HTLV-I-infected cells the presence of a novel viral protein, HBZ, encoded by the complementary strand of the HTLV-I RNA genome (Gaudray, G., Gachon, F., Basbous, J., Biard-Piechaczyk, M., Devaux, C., and Mesnard, J.-M. (2002) J. Virol. 76, 12813–12822). HBZ is a nuclear basic leucine zipper protein that down-regulates Tax-dependent viral transcription by inhibiting the binding of cAMP-response element-binding protein-2 to the HTLV-I promoter. In searching for other cellular targets of HBZ, we identified two members of the Jun family, JunB and c-Jun. Co-immunoprecipitation and cellular colocalization confirmed that HBZ interacts in vivo with JunB and c-Jun. When transiently introduced into CEM cells with a reporter gene containing the AP-1 site from the collagenase promoter, HBZ suppressed transactivation by c-Jun. On the other hand, the combination of HBZ with Jun-B had higher transcriptional activity than JunB alone. Consistent with the structure of its basic domain, we demonstrate that HBZ decreases the DNA-binding activity of c-Jun and JunB. Last, we show that c-Jun is no longer capable of activating the basal expression of the HTLV-I promoter in the presence of HBZ in vivo. Our results support the hypothesis that HBZ could be a negative modulator of the Tax effect by controlling Tax expression at the transcriptional level and by attenuating activation of AP-1 by Tax.

4 March 2004 in FEBS Letters
Verified
Journal Article
Closed access
STSabine Thébault
Sabine Thébault
JBJihane Basbous
Jihane Basbous
PHPatrick Hivin
Patrick Hivin
CDChristian A. Devaux
Christian A. Devaux
JMJean-Michel Mesnard
Jean-Michel Mesnard

1 March 2021 in Molecular Cell
Verified
Journal Article
Closed access
CFCamilla Frattini
Camilla Frattini
APAlexy Promonet
Alexy Promonet
EAEmile Alghoul
Emile Alghoul
SVSophie Vidal-Eychenie
Sophie Vidal-Eychenie
MLMarie Lamarque
Marie Lamarque
ACAngelos Constantinou
Angelos Constantinou

1 June 2007 in Molecular and Cellular Biology
Verified
Journal Article
Closed access
JBJihane Basbous
Jihane Basbous
DCDany Chalbos
Dany Chalbos
RHRobert Hipskind
Robert Hipskind
IJIsabelle Jariel-Encontre
Isabelle Jariel-Encontre
MPMarc Piechaczyk
Marc Piechaczyk
Fra-1, a transcription factor that is phylogenetically and functionally related to the proto-oncoprotein c-Fos, controls many essential cell functions. It is expressed in many cell types, albeit with differing kinetics and abundances. In cells reentering the cell cycle, Fra-1 expression is transiently stimulated albeit later than that of c-Fos and for a longer time. Moreover, Fra-1 overexpression is found in cancer cells displaying high Erk1/2 activity and has been linked to tumorigenesis. One crucial point of regulation of Fra-1 levels is controlled protein degradation, the mechanism of which remains poorly characterized. Here, we have combined genetic, pharmacological, and signaling studies to investigate this process in nontransformed cells and to elucidate how it is altered in cancer cells. We report that the intrinsic instability of Fra-1 depends on a single destabilizer contained within the C-terminal 30 to 40 amino acids. Two serines therein, S252 and S265, are phosphorylated by kinases of the Erk1/2 pathway, which compromises protein destruction upon both normal physiological induction and tumorigenic constitutive activation of this cascade. Our data also indicate that Fra-1, like c-Fos, belongs to a small group of proteins that may, under certain circumstances, undergo ubiquitin-independent degradation by the proteasome. Our work reveals both similitudes and differences between Fra-1 and c-Fos degradation mechanisms. In particular, the presence of a single destabilizer within Fra-1, instead of two that are differentially regulated in c-Fos, explains the much faster turnover of the latter when cells traverse the G(0)/G(1)-to-S-phase transition. Finally, our study offers further insights into the signaling-regulated expression of the other Fos family proteins.